In this case I'd imagine it means that the market is waiting for...

In this case I'd imagine it means that the market is waiting for direction. Thank goodness the market is more rational than all the dreamers here.
Catalyst will come once we have updates to outcomes of the patient experience, then actual sales figures, stickiness of the sales figures, actual field efficacy compared to competing products and product uptake, then we better hope that insurance companies don't have any adverse reaction to Sofdra and increase co-pay etc etc.
Until some of these start filtering through, I personally don't think this will move too much. MC is already priced in a promising trajectory considering potential risks.